Redeye raises its valuation on Episurf Medical but lowers near term estimates due to the corona crisis, which has halted elective surgeries. Our medium to long term conviction is enhanced, however, as we find the company’s extensive clinical pipeline promising and its substantial recent capital injection very reassuring.